Inventor · disambiguated record
Xiaolin Tang
Also filed as: TANG XIAOLIN
15 granted patents·28 pending applications·307 citations·filing 2003–2025
93Inventor score
Top patents by PatentIndex Score
43 records- 0196US8945559B2Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodiesDIX DANIEL B·Filed 2011·Granted Feb 3, 2015·139 cites·25 claims
- 0295US10435473B2Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodiesREGENERON PHARMA·Filed 2017·Granted Oct 8, 2019·18 cites·21 claims
- 0395US10342876B2Process for reducing subvisible particles in a pharmaceutical formulationREGENERON PHARMA·Filed 2015·Granted Jul 9, 2019·17 cites·21 claims
- 0495US9238692B2Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodiesREGENERON PHARMA·Filed 2014·Granted Jan 19, 2016·26 cites·22 claims
- 0593US12066246B2Target residual moisture content for lyophilized drug productREGENERON PHARMA·Filed 2023·Granted Aug 20, 2024·2 cites·20 claims
- 0693US6971187B1Automated process control using manometric temperature measurementPURDUE RESEARCH FOUNDATION·Filed 2003·Granted Dec 6, 2005·84 cites·16 claims
- 0792US11525629B2Target residual moisture content for lyophilized drug productREGENERON PHARMA·Filed 2021·Granted Dec 13, 2022·4 cites·20 claims
- 0892US11059896B2Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodiesREGENERON PHARMA·Filed 2019·Granted Jul 13, 2021·3 cites·45 claims
- 0991US11713922B2Target residual moisture content for lyophilized drug productREGENERON PHARMA·Filed 2022·Granted Aug 1, 2023·3 cites·15 claims
- 1090US11926670B2Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodiesREGENERON PHARMA·Filed 2021·Granted Mar 12, 2024·1 cites·23 claims
- 1189US2024360230A1Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) AntibodiesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1288US11351256B2Room temperature stable lyophilized proteinREGENERON PHARMA·Filed 2017·Granted Jun 7, 2022·9 cites·19 claims
- 1386US12449198B2Target residual moisture content for lyophilized drug productREGENERON PHARMA·Filed 2024·Granted Oct 21, 2025·0 cites·19 claims
- 1484US2024415969A1Process for reducing subvisible particles in a pharmaceutical formulationREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1582US2023348532A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1682US2023331776A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1782US2023332084A1Bioreactor for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1882US2023287043A1Cell culture methods for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1982US2023332201A1Cell culture methods for antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2082US2024010737A1Manufacturing process for high titer antibodyREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2180US2025281618A1Process for reducing subvisible particles in a pharmaceutical formulationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2279US11241498B2Room temperature stable lyophilized proteinREGENERON PHARMA·Filed 2019·Granted Feb 8, 2022·1 cites·16 claims
- 2373US12070502B2Process for reducing subvisible particles in a pharmaceutical formulationREGENERON PHARMA·Filed 2019·Granted Aug 27, 2024·0 cites·48 claims
- 2471US2025161457A1Process for reducing subvisible particles in a pharmaceutical formulationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2570US2024335534A1Methods of reducing particle formation and compositions formed therebyREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2669US2025179177A1Stable antibody formulationREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2767US2025312447A1Methods of reducing particle formation and compositions formed therebyREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2864US2025236677A1Stabilized Formulations Containing Anti-CD20 x Anti-CD3 Bispecific AntibodiesREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2963US2024024472A1Anti-Interleukin-4 Receptor (IL-4R) Antibody FormulationsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3062US2024352103A1Anti-fel d1 antibody formulationsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3162US2025109905A1Lyophilization using controlled nucleationREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3260US2025145662A1Methods for reducing lipase activity using stressREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3360US2016102147A1Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) AntibodiesREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 3460US2024175027A1Anti-c5 antibody/c5 irna co-formulations and combination therapiesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3560US2021206870A1Stabilized Formulations Containing Anti-CD20 x Anti-CD3 Bispecific AntibodiesREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 3659US12042538B2Methods of reducing particle formation and compositions formed therebyREGENERON PHARMA·Filed 2018·Granted Jul 23, 2024·0 cites·21 claims
- 3758US2024199688A1Methods for reducing lipase activityREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3856US2024366471A1Multidose antibody drug products using phenol or benzyl alcoholREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3953US2022139558A1Methods and systems for biotherapeutic developmentREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4053US2022031843A1Stabilized Formulations Containing Anti-CTLA-4 AntibodiesREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4152US2024360591A1Methods for selecting excipients and for preparing high concentration monoclonal antibody formulations and other formulations comprising proteinsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4250US2021046182A1High concentration anti-c5 formulationsREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4340US2019021952A1Stabilized Antibody Compositions and Methods of Producing SameREGENERON PHARMA·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xiaolin Tang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →